Female reproductive health in cystic fibrosis
Female reproductive health in cystic fibrosis
复制标题
DOI：
10.1016/j.jcf.2019.08.024
复制
发表时间：
2019-10-01
影响因子：
5.2
通讯作者：
Roe, Andrea
中科院分区：
文献类型：
--
作者：
Hughan, Kara S.;Daley, Tanicia;Roe, Andrea
患有囊性纤维化（CF）的女性寿命更长，生活更健康，生育的机会越来越有希望。然而，这一人群也可能面临性健康和生殖健康问题，包括月经不规律、意外怀孕、不孕症和妊娠并发症。此外，越来越多的妇女进入更年期，并处于雌激素缺乏的后果的风险。CF中女性生殖健康状况的确切机制尚不清楚，但被认为包括囊性纤维化跨膜调节因子（CFTR）介导的异常，女性性激素的变化和其他CF健康相关因素。在CFTR调节剂治疗的时代，需要新的数据来了解CFTR调节对避孕有效性，生育力和妊娠结局的影响，以帮助指导未来的临床护理。本文综述了目前的科学知识的主要生殖健康问题的妇女与CF。(C)2019年，任作家。由Elsevier B.V.代表欧洲囊性纤维化协会出版。
Women with cystic fibrosis (CF) are living longer and healthier lives, and opportunities for childbearing are increasingly promising. However, this population can also face sexual and reproductive health concerns, including menstrual irregularities, unplanned pregnancies, infertility and pregnancy complications. Additionally, more women are entering menopause and are at risk for the consequences of estrogen deficiency. The exact mechanisms involved in female reproductive health conditions in CF are not clearly understood, but are thought to include cystic fibrosis transmembrane regulator (CFTR)-mediated abnormalities, changes in female sex hormones, and other CF health-related factors. In the era of CFTR modulator therapy, new data are necessary to understand the impact of CFTR modulation on contraceptive effectiveness, fertility, and pregnancy outcomes to help guide future clinical care. This article reviews the current scientific knowledge of major reproductive health issues for women with CF. (C) 2019 The Authors. Published by Elsevier B.V. on behalf of European Cystic Fibrosis Society.